ADAPT支架蛋白的放射性核素肿瘤靶向:标记位置及标记残留化特性的影响
研究在SKOV-3卵巢癌异种移植小鼠中比较Cys2-ADAPT6与Cys59-ADAPT6分别用111In-DOTA或125I-HPEM标记后的HER2靶向和生物分布。结果显示标记残留化特性强烈影响ADAPT6靶向性能,标记位置亦有影响;C端标记对放射性金属和放射性卤素标记均获得最佳生物分布特征。
要点
- 125I-HPEM标记较111In-DOTA标记在注射后4小时肾脏摄取低140倍以上。
- 111In-DOTA-Cys59-ADAPT6较111In-DOTA-Cys2-ADAPT6显著提高肿瘤/肺、肿瘤/肝、肿瘤/脾和肿瘤/肌肉比值。
- 125I-HPEM-Cys59-ADAPT6较另一放射性碘标记变体显著提高肿瘤摄取和肿瘤/肾比值。
核心结论
- 标记的残留化特性强烈影响ADAPT6的靶向性能,标记位置亦有影响但程度较小。
- C端放置标记对放射性金属和放射性卤素标记均产生最佳生物分布特征。
- 放射性碘标记的低肾脏滞留为使用131I标记的HPEM-Cys59-ADAPT6进行放射性核素治疗创造了前提条件。
研究设计与样本
- 制备在N端具有(HE)3DANS序列的Cys2-ADAPT6和Cys59-ADAPT6两种构建体,并用111In-DOTA或125I-HPEM进行位点特异性标记。
- 在体外和体内比较偶联物,在荷SKOV-3卵巢癌异种移植的BALB/C nu/nu小鼠中评估HER2靶向性能和生物分布。
主要发现
- 标记后特异性HER2结合和高亲和力得以保留,Cys2-ADAPT6和Cys59-ADAPT6均被HER2表达癌细胞缓慢内化。
- 注射后4小时肿瘤摄取随标记位置不同为每克肿瘤组织注射剂量的10%至22%。
- 注射后4小时,无论标记位于哪一端,125I-HPEM标记的肾脏摄取较111In-DOTA标记低140倍以上。
- 111In-DOTA标记的Cys2-ADAPT6与Cys59-ADAPT6肿瘤/血比值无显著差异(250-280),但111In-DOTA-Cys59-ADAPT6的肿瘤/肺、肿瘤/肝、肿瘤/脾和肿瘤/肌肉比值显著更高。
- 放射性碘标记变体肿瘤/器官比值相似,但125I-HPEM-Cys59-ADAPT6肿瘤摄取更高且肿瘤/肾比值更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Visualization of cancer-associated alterations of molecular phenotype using radionuclide imaging is a noninvasive approach to stratifying patients for targeted therapies. The engineered albumin-binding domain-derived affinity protein (ADAPT) is a promising tracer for radionuclide molecular imaging because of its small size (6.5 kDa), which satisfies the precondition for efficient tumor penetration and rapid clearance. Previous studies demonstrated that the human epidermal growth factor receptor type 2 (HER2)-targeting ADAPT6 labeled with radiometals at the N terminus is able to image HER2 expression in xenografts a few hours after injection. The aim of this study was to evaluate whether the use of a nonresidualizing label or placement of the labels at the C terminus would further improve the targeting properties of ADAPT6. Methods: Two constructs, Cys2-ADAPT6 and Cys59-ADAPT6, having the (HE)3DANS sequence at the N terminus were produced and site-specifically labeled using 111In-DOTA or 125I-iodo-((4-hydroxyphenyl)ethyl) maleimide (HPEM). The conjugates were compared in vitro and in vivo. HER2-targeting properties and biodistribution were evaluated in BALB/C nu/nu mice bearing ovarian carcinoma cell (SKOV-3) xenografts. Results: Specific HER2 binding and high affinity were preserved after labeling. Both Cys2-ADAPT6 and Cys59-ADAPT6 were internalized slowly by HER2-expressing cancer cells. Depending on the label position, uptake at 4 h after injection varied from 10% to 22% of the injected dose per gram of tumor tissue. Regardless of terminus position, the 125I-HPEM label provided more than 140-fold lower renal uptake than the 111In-DOTA label at 4 after injection. The tumor-to-organ ratios were, in contrast, higher for both of the 111In-DOTA-labeled ADAPT variants in other organs. Tumor-to-blood ratios for 111In-labeled Cys2-ADAPT6 and Cys59-ADAPT6 did not differ significantly (250-280), but 111In-DOTA-Cys59-ADAPT6 provided significantly higher tumor-to-lung, tumor-to-liver, tumor-to-spleen, and tumor-to-muscle ratios. Radioiodinated variants had similar tumor-to-organ ratios, but 125I-HPEM-Cys59-ADAPT6 had significantly higher tumor uptake and a higher tumor-to-kidney ratio. Conclusion: Residualizing properties of the label strongly influence the targeting properties of ADAPT6. The position of the radiolabel influences targeting as well, although to a lesser extent. Placement of a label at the C terminus yields the best biodistribution features for both radiometal and radiohalogen labels. Low renal retention of the radioiodine label creates a precondition for radionuclide therapy using 131I-labeled HPEM-Cys59-ADAPT6.
引用
- Lindbo S, Garousi J, Mitran B, et al. Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label. J Nucl Med. 2017. PMID: 28864631. doi:10.2967/jnumed.117.197202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。